Neutropenia

Latest News
October 4th 2019

The Long-term Social Value of Granulocyte Colony-Stimulating Factors

April 15th 2019

The Conundrum Of Antibacterial Use in Neutropenic Patients Undergoing Chemotherapy for Hematologic Malignancy or HSCT

March 2nd 2019

Neutropenia Etiology Influences Resulting Hematologic Consequences

February 27th 2019

Patients With mCRPC Have Lower Risk of Severe Neutropenia

February 22nd 2019

Home Monitoring Device for Blood Cell, Neutrophil Counts Shows Positive Initial Results

Video Interviews
View All
January 3rd 2019

Dr Alison Moskowitz on Treatments More Likely to Cause Neutropenia in Hodgkin Lymphoma

December 20th 2018

Dr Elizabeth Griffiths on Predicting Neutropenia in Patients With AML

December 15th 2018

Beth Wittmer Discusses Diet Restrictions With Neutropenia

December 7th 2018

Beth Wittmer on Keeping Patients With Neutropenia Out of the Emergency Department

November 22nd 2018

Beth Wittmer on Educating Patients on Neutropenia as a Side of Effect of Cancer Treatment

More News

Multiday Corticosteroid Administration Delays Diagnosis, Treatment of Febrile Neutropenia
February 19th 2019

Multiday Corticosteroid Administration Delays Diagnosis, Treatment of Febrile Neutropenia

Jaime Rosenberg
Researchers have found that multiday corticosteroid administration during chemotherapy delays the diagnosis of and antimicrobial administration for febrile neutropenia.
Researchers Characterize Epidemiology of, Source of Infection in Febrile Neutropenia
February 16th 2019

Researchers Characterize Epidemiology of, Source of Infection in Febrile Neutropenia

Jaime Rosenberg
Researchers have determined that febrile neutropenia has a low rate of bacteremia and approximately half of patients receive the recommended initial empiric therapy.
D-Index–Guided Therapy Reduces Use of Antifungals Without Increasing Infection, Mortality in Febrile Neutropenia
February 14th 2019

D-Index–Guided Therapy Reduces Use of Antifungals Without Increasing Infection, Mortality in Febrile Neutropenia

Jaime Rosenberg
A study has demonstrated that D-index–guided early antifungal therapy, a novel approach to treating persistent or recurrent febrile neutropenia, is feasible in high-risk patients with neutropenia.
Continuous Temperature-Monitoring Skin Patch Effective for Detecting Febrile Neutropenia Earlier
February 8th 2019

Continuous Temperature-Monitoring Skin Patch Effective for Detecting Febrile Neutropenia Earlier

Jaime Rosenberg
According to a study abstract presented at the 60th American Society of Hematology Annual Meeting & Exposition, using a skin patch for continuous temperature monitoring is feasible in the inpatient setting and has the potential to detect febrile neutropenia earlier.
On-Body Injector as Effective as Manual Injection of Pegfilgrastim for Preventing Febrile Neutropenia
February 3rd 2019

On-Body Injector as Effective as Manual Injection of Pegfilgrastim for Preventing Febrile Neutropenia

Jaime Rosenberg
In 2015, the Neulasta On-Body Injector (OBI) Onpro device was introduced as a less costly method of pegfilgrastim administration. While the device has been found to be safe in healthy volunteers and have pharmacokinetics similar to that of traditional pegfilgrastim, there have been limited data comparing the 2 methods.
Over the Past 2 Decades, Use of G-CSF in Non-Hodgkin Lymphoma Increased Significantly
February 1st 2019

Over the Past 2 Decades, Use of G-CSF in Non-Hodgkin Lymphoma Increased Significantly

Jaime Rosenberg
Among older patients with non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) increased significantly over the past 20 years.
Researchers Determine Frequency of Bloodstream Infections in Patients With Febrile Neutropenia
January 26th 2019

Researchers Determine Frequency of Bloodstream Infections in Patients With Febrile Neutropenia

Jaime Rosenberg
Examining the frequency of bloodstream infection in these patients, researchers have found that staphylococcus aureus is most prevalent, followed by Klebsiella and E. coli.
Researchers Study Pediatric FN Episodes to Predict Risk of Complications, Validate Clinical Decision Rules
January 23rd 2019

Researchers Study Pediatric FN Episodes to Predict Risk of Complications, Validate Clinical Decision Rules

Jaime Rosenberg
Seeking to generate data for the development and validation of clinical decision rules in pediatric febrile neutropenia (FN), researchers used 2 decades of data on FN episodes in pediatric patients.
PCT Just as Effective as MASCC for Predicting Serious Complications in Febrile Neutropenia
January 19th 2019

PCT Just as Effective as MASCC for Predicting Serious Complications in Febrile Neutropenia

Jaime Rosenberg
A single measurement of procalcitonin (PCT) is comparable to Multinational Association for Supportive Care in Cancer (MASCC) score for predicting serious medical complications in patients with cancer with febrile neutropenia.
Cefepime Administered by IV Push Associated With Increased Risk of Neutropenia
January 17th 2019

Cefepime Administered by IV Push Associated With Increased Risk of Neutropenia

Jaime Rosenberg
More than 2 weeks of treatment with cefepime administered by intravenous (IV) push significantly increases the risk of cefepime-induced neutropenia.
Early Granulocyte Transfusions Increase Survival Rates in Neutropenia With Multidrug-Resistant Organisms
January 11th 2019

Early Granulocyte Transfusions Increase Survival Rates in Neutropenia With Multidrug-Resistant Organisms

Jaime Rosenberg
Patients with neutropenia who have multidrug-resistant organisms have better rates of overall survival when receiving granulocyte transfusions within 7 days of neutropenic sepsis.
Study Finds CISNE Model Effective for Guiding Treatment-Setting Decisions for Febrile Neutropenia
January 9th 2019

Study Finds CISNE Model Effective for Guiding Treatment-Setting Decisions for Febrile Neutropenia

Jaime Rosenberg
A new study comparing 2 risk stratification models found that the Clinical Index of Stable Febrile Neutropenia (CISNE) Model is useful for identifying low-risk patients with febrile neutropenia, but the combination of the CISNE Model with the Multinational Association of Supportive Care in Cancer Risk Index Score may help emergency physicians cope with febrile neutropenia more confidently.
Alternating First-Line Antibiotics Increases Heterogeneity Without Increasing Mortality in Febrile Neutropenia
January 3rd 2019

Alternating First-Line Antibiotics Increases Heterogeneity Without Increasing Mortality in Febrile Neutropenia

Jaime Rosenberg
Assessing the alternation of first-line antibiotics to avoid antibiotic resistance, researchers have determined that the strategy results in an increase in heterogeneity without increasing mortality.
Neutropenia Independently Associated With Poor Outcomes, but Not When Treated With G-CSF
December 28th 2018

Neutropenia Independently Associated With Poor Outcomes, but Not When Treated With G-CSF

Jaime Rosenberg
Despite a meaningful survival, neutropenia is independently associated with poor outcomes among critically ill patients with cancer, according to a new study. However, neutropenia was no longer significantly associated with outcome in patients treated with granulocyte colony-stimulating factor (G-CSF), suggesting a beneficial impact of the treatment.
Similar Incidence Rates of Febrile Neutropenia Between Short- and Long-Acting G-CSFs
December 27th 2018

Similar Incidence Rates of Febrile Neutropenia Between Short- and Long-Acting G-CSFs

David Bai, PharmD
Incidence of febrile neutropenia, hospitalizations, and chemotherapy dose reductions and/or delays were similar between short- and long-acting granulocyte-colony stimulating factors, according to a meta-analysis of randomized controlled trials.
Studies Find High Prevalence, Cost of Neutropenia in Pediatric Patients With Autoimmune Disease
December 18th 2018

Studies Find High Prevalence, Cost of Neutropenia in Pediatric Patients With Autoimmune Disease

David Bai, PharmD
Pediatric patients with autoimmune neutropenia have a higher prevalence and cost than previously suspected, according to the results of 2 studies presented at the 60th American Society of Hematology Annual Meeting & Exposition, held December 1-4 in San Diego, California.
Severe Neutropenia May Predict Survival Outcomes in Patients With Pancreatic Cancer
December 5th 2018

Severe Neutropenia May Predict Survival Outcomes in Patients With Pancreatic Cancer

David Bai, PharmD
Among patients with pancreatic cancer being treated with modified FOLFIRINOX, those who develop severe neutropenia have significantly longer median overall survival, as well as longer time to treatment failure, compared with those who do not develop severe neutropenia.
Management and Prevention of Febrile Neutropenia: Updated Guidelines
November 30th 2018

Management and Prevention of Febrile Neutropenia: Updated Guidelines

Jaime Rosenberg
New clinical guidelines are providing guidance for clinicians on the diagnosis, prevention, and treatment of febrile neutropenia in adult patients with solid tumors.
Outpatient ASCT Safe, Results in Lower Rates of Febrile Neutropenia and Septicemia
November 29th 2018

Outpatient ASCT Safe, Results in Lower Rates of Febrile Neutropenia and Septicemia

David Bai, PharmD
Patients who undergo outpatient autologous stem cell transplantations (ASCTs) not only report lower costs and higher satisfaction, but they also have lower odds of developing febrile neutropenia and septicemia than patients who undergo inpatient ASCT, according to the results of a new analysis.
Congenital Severe Neutropenia Presents With Different Clinical, Hematological Findings Than Noncongenital Neutropenia
November 22nd 2018

Congenital Severe Neutropenia Presents With Different Clinical, Hematological Findings Than Noncongenital Neutropenia

David Bai, PharmD
Greater infection rate, higher white blood cell, monocyte, and absolute neutrophil counts are more significantly associated with severe congenital neutropenia than with patients with idiopathic and recovered neutropenia, according study results.
Assessment Can Help ED Physicians Predict Poor Prognosis for Patients With Febrile Neutropenia
November 17th 2018

Assessment Can Help ED Physicians Predict Poor Prognosis for Patients With Febrile Neutropenia

Jaime Rosenberg
The quick sequential (sepsis-related) organ failure assessment can help emergency department physicians identify which patients with neutropenia are at risk of a poor prognosis and should receive prompt empirical antimicrobial therapy, according to a new study.
Study Identifies High Burden of Invasive Infections in Neutropenic Patients
November 15th 2018

Study Identifies High Burden of Invasive Infections in Neutropenic Patients

Jaime Rosenberg
One-third of neutropenic patients developed invasive infection following intensive chemotherapy, which was significantly associated with an increase in mortality up to 100 days after the start of neutropenia.
Characteristics and Management of Patients With Febrile Neutropenia
November 10th 2018

Characteristics and Management of Patients With Febrile Neutropenia

David Bai, PharmD
Seeking to determine how FN is managed in most referral hospitals in Iran, researchers studied patients hospitalized during a 6-month period, also taking into account characteristics of FN patients and the risk factors associated with FN development.
AJMC® in the Press, November 9, 2018
November 9th 2018

AJMC® in the Press, November 9, 2018

AJMC Staff
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Febrile Neutropenia Following Chemotherapy Predicts Long-Term Risk of Infection
November 6th 2018

Febrile Neutropenia Following Chemotherapy Predicts Long-Term Risk of Infection

Jaime Rosenberg
Adjusted incidence rate ratios showed that febrile neutropenia following chemotherapy carried an approximately 2-fold risk of long-term infection.
Cytarabine, Aclarubicin, and G-CSF Effective Treatment Regimen for Relapsed/Refractory AML
November 3rd 2018

Cytarabine, Aclarubicin, and G-CSF Effective Treatment Regimen for Relapsed/Refractory AML

David Bai, PharmD
Cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CAG) generates a positive effect for patients with acute myeloid leukemia (AML) by decreasing the number of immunosuppressive cell types and their associated cytokines, while also downregulating SDF-1α levels
Patients With HIV at Greater Risk of Neutropenia, Not Completing Chemoradtiotherapy
October 31st 2018

Patients With HIV at Greater Risk of Neutropenia, Not Completing Chemoradtiotherapy

Jaime Rosenberg
Among women with HIV, there is an increased risk of neutropenia during chemoradiotherapy treatment for cervical cancer and they are less likely to complete chemotherapy with cisplatin.
Colony-Stimulating Factors Can Help Treat, Prevent Clozapine-Induced Neutropenia or Leukopenia
October 24th 2018

Colony-Stimulating Factors Can Help Treat, Prevent Clozapine-Induced Neutropenia or Leukopenia

David Bai, PharmD
A case report has revealed that clozapine with intermittent colony-stimulating factors helped treat leukopenia and neutropenia in a patient with chronic paranoid schizophrenia who responds only to clozapine.
Dermatologic/Mucosal Conditions, Corticosteroids, Intravenous Antibiotics Impact Febrile Neutropenia Risk
October 22nd 2018

Dermatologic/Mucosal Conditions, Corticosteroids, Intravenous Antibiotics Impact Febrile Neutropenia Risk

Jaime Rosenberg
Certain dermatologic/mucosal conditions, use of corticosteroids, and intravenous antibiotics prior to chemotherapy may increase the risk of febrile neutropenia.
New Tool Provides Cycle-Specific Score to Predict Febrile Neutropenia After Chemotherapy
October 19th 2018

New Tool Provides Cycle-Specific Score to Predict Febrile Neutropenia After Chemotherapy

David Bai, PharmD
Researchers developed and validated a risk score to predict febrile neutropenia in cycles 2 to 6 of chemotherapy.
1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo